Mechanisms of complement activation by dextran-coated superparamagnetic iron oxide (SPIO) nanoworms in mouse versus human serum

Particle and Fibre Toxicology

Volumn 11, Issue 1, 2014, Pages

  Banda, Nirmal K ^a   Mehta, Gaurav ^a   Chao, Ying ^b   Wang, Guankui ^c   Inturi, Swetha ^c   Fossati Jimack, Liliane ^d   Botto, Marina ^d   Wu, LinPing ^e   Moghimi, Seyed Moein ^e,f   Simberg, Dmitri ^c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4D; DEXTRAN; DEXTRAN COATED SUPERPARAMAGNETIC IRON OXIDE NANOWORM; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; COMPLEMENT; CONTRAST MEDIUM; MAGNETITE NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE;

ANTIGEN BINDING; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT DEPOSITION; COMPLEMENT LECTIN PATHWAY; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; HUMAN; IN VITRO STUDY; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; SPECIES COMPARISON; ADULT; ANIMAL; BLOOD; C57BL MOUSE; COMPARATIVE STUDY; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; MALE; METABOLISM; SPECIES DIFFERENCE; SURFACE PROPERTY;

ADULT; ANIMALS; BIOMARKERS; COMPLEMENT ACTIVATION; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT PATHWAY, CLASSICAL; COMPLEMENT PATHWAY, MANNOSE-BINDING LECTIN; COMPLEMENT SYSTEM PROTEINS; CONTRAST MEDIA; DEXTRANS; HUMANS; MAGNETITE NANOPARTICLES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; SPECIES SPECIFICITY; SURFACE PROPERTIES;

EID: 84964697568     PISSN: None     EISSN: 17438977     Source Type: Journal    
DOI: 10.1186/s12989-014-0064-2     Document Type: Article

References (54)

1. Figuerola A, Di Corato R, Manna L, Pellegrino T: From iron oxide nanoparticles towards advanced iron-based inorganic materials designed for biomedical applications. Pharmacol Res 2010, 62:126-143.
2. Gupta AK, Gupta M: Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005, 26:3995-4021.
3. Bulte JW, Kraitchman DL: Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed 2004, 17:484-499.
4. Ricklin D, Hajishengallis G, Yang K, Lambris JD: Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010, 11:785-797.
5. Janssen BJC, Huizinga EG, Raaijmakers HCA, Roos A, Daha MR, Nilsson-Ekdahl K, Nilsson B, Gros P: Structures of complement component C3 provide insights into the function and evolution of immunity. Nature 2005, 437:505-511.
6. Ali YM, Lynch NJ, Haleem KS, Fujita T, Endo Y, Hansen S, Holmskov U, Takahashi K, Stahl GL, Dudler T, Girija UV, Wallis R, Kadioglu A, Stover CM, Andrew PW, Schwaeble WJ: The lectin pathway of complement activation is a critical component of the innate immune response to pneumococcal infection. Plos Pathog 2012, 8:e1002793.
7. Moghimi SM, Farhangrazi ZS: Nanomedicine and the complement paradigm. Nanomedicine 2013, 9:458-460.
8. Helmy KY, Katschke KJ Jr, Gorgani NN, Kljavin NM, Elliott JM, Diehl L, Scales SJ, Ghilardi N, van Lookeren CM: CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell 2006, 124:915-927.
9. Taylor PR, Martinez-Pomares L, Stacey M, Lin HH, Brown GD, Gordon S: Macrophage receptors and immune recognition. Annu Rev Immunol 2005, 23:901-944.
10. Peng Q, Li K, Sacks SH, Zhou W: The role of anaphylatoxins C3a and C5a in regulating innate and adaptive immune responses. Inflamm Allergy Drug Targets 2009, 8:236-246.
11. Szebeni J: Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 2005, 216:106-121.
12. Andersen AJ, Hashemi SH, Andresen TL, Hunter AC, Moghimi SM: Complement: alive and kicking nanomedicines. J Biomed Nanotechnol 2009, 5:364-372.
13. Pedersen MB, Zhou X, Larsen EK, Sorensen US, Kjems J, Nygaard JV, Nyengaard JR, Meyer RL, Boesen T, Vorup-Jensen T: Curvature of synthetic and natural surfaces is an important target feature in classical pathway complement activation. J Immunol 2010, 184:1931-1945.
14. Andersen AJ, Robinson JT, Dai H, Hunter AC, Andresen TL, Moghimi SM: Single-walled carbon nanotube surface control of complement recognition and activation. ACS Nano 2013, 7:1108-1119.
15. Peracchia MT, Vauthier C, Passirani C, Couvreur P, Labarre D: Complement consumption by poly(ethylene glycol) in different conformations chemically coupled to poly(isobutyl 2-cyanoacrylate) nanoparticles. Life Sci 1997, 61:749-761.
16. Pham CT, Mitchell LM, Huang JL, Lubniewski CM, Schall OF, Killgore JK, Pan D, Wickline SA, Lanza GM, Hourcade DE: Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces. J Biol Chem 2011, 286:123-130.
17. Al-Hanbali O, Rutt KJ, Sarker DK, Hunter AC, Moghimi SM: Concentration dependent structural ordering of poloxamine 908 on polystyrene nanoparticles and their modulatory role on complement consumption. J Nanosci Nanotechnol 2006, 6:3126-3133.
18. Moghimi SM, Hamad I, Andresen TL, Jorgensen K, Szebeni J: Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. Faseb J 2006, 20:2591-2593.
19. Salvador-Morales C, Zhang L, Langer R, Farokhzad OC: Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials 2009, 30:2231-2240.
20. Moore A, Weissleder R, Bogdanov A Jr: Uptake of dextran-coated monocrystalline iron oxides in tumor cells and macrophages. J Magn Reson Imaging 1997, 7:1140-1145.
21. Simberg D, Park JH, Karmali PP, Zhang WM, Merkulov S, McCrae K, Bhatia SN, Sailor M, Ruoslahti E: Differential proteomics analysis of the surface heterogeneity of dextran iron oxide nanoparticles and the implications for their in vivo clearance. Biomaterials 2009, 30:3926-3933.
22. Turner MW: Mannose-binding lectin: the pluripotent molecule of the innate immune system. Immunol Today 1996, 17:532-540.
23. Karmali PP, Chao Y, Park JH, Sailor MJ, Ruoslahti E, Esener SC, Simberg D: Different effect of hydrogelation on antifouling and circulation properties of dextran-iron oxide nanoparticles. Mol Pharm 2012, 9:539-545.
24. Chao Y, Karmali PP, Mukthavaram R, Kesari S, Kouznetsova VL, Tsigelny IF, Simberg D: Direct recognition of superparamagnetic nanocrystals by macrophage scavenger receptor SR-AI. ACS Nano 2013, 7:4289-4298.
25. Chao Y, Makale M, Karmali PP, Sharikov Y, Tsigelny I, Merkulov S, Kesari S, Wrasidlo W, Ruoslahti E, Simberg D: Recognition of dextran-superparamagnetic iron oxide nanoparticle conjugates (Feridex) via macrophage scavenger receptor charged domains. Bioconjug Chem 2012, 23:1003-1009.
26. Molday RS, MacKenzie D: Immunospecific ferromagnetic iron-dextran reagents for the labeling and magnetic separation of cells. J Immunol Methods 1982, 52:353-367.
27. Jung CW, Jacobs P: Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging 1995, 13:661-674.
28. Jung CW: Surface properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging 1995, 13:675-691.
29. Cunnion KM, Hair PS, Buescher ES: Cleavage of complement C3b to iC3b on the surface of Staphylococcus aureus is mediated by serum complement factor I. Infect Immun 2004, 72:2858-2863.
30. Fujita T, Matsushita M, Endo Y: The lectin-complement pathway-its role in innate immunity and evolution. Immunol Rev 2004, 198:185-202.
31. Takahashi M, Iwaki D, Kanno K, Ishida Y, Xiong J, Matsushita M, Endo Y, Miura S, Ishii N, Sugamura K, Fujita T: Mannose-binding lectin (MBL)-associated serine protease (MASP)-1 contributes to activation of the lectin complement pathway. J Immunol 2008, 180:6132-6138.
32. Banda NK, Takahashi M, Takahashi K, Stahl GL, Hyatt S, Glogowska M, Wiles TA, Endo Y, Fujita T, Holers VM, Arend WP: Mechanisms of mannose-binding lectin-associated serine proteases-1/3 activation of the alternative pathway of complement. Mol Immunol 2011, 49:281-289.
33. Banda NK, Takahashi M, Levitt B, Glogowska M, Nicholas J, Takahashi K, Stahl GL, Fujita T, Arend WP, Holers VM: Essential role of complement mannose-binding lectin-associated serine proteases-1/3 in the murine collagen antibody-induced model of inflammatory arthritis. J Immunol 2010, 185:5598-5606.
34. Selander B, Martensson U, Weintraub A, Holmstrom E, Matsushita M, Thiel S, Jensenius JC, Truedsson L, Sjoholm AG: Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2. J Clin Invest 2006, 116:1425-1434.
35. Suankratay C, Zhang XH, Zhang Y, Lint TF, Gewurz H: Requirement for the alternative pathway as well as C4 and C2 in complement-dependent hemolysis via the lectin pathway. J Immunol 1998, 160:3006-3013.
36. Mestas J, Hughes CCW: Of mice and not men: differences between mouse and human immunology. J Immunol 2004, 172:2731-2738.
37. Bertholon I, Vauthier C, Labarre D: Complement activation by core-shell poly(isobutylcyanoacrylate)-polysaccharide nanoparticles: influences of surface morphology, length, and type of polysaccharide. Pharm Res 2006, 23:1313-1323.
38. Labarre D, Vauthier C, Chauvierre C, Petri B, Muller R, Chehimi MM: Interactions of blood proteins with poly(isobutylcyanoacrylate) nanoparticles decorated with a polysaccharidic brush. Biomaterials 2005, 26:5075-5084.
39. Hamad I, Hunter AC, Moghimi SM: Complement monitoring of Pluronic 127 gel and micelles: Suppression of copolymer-mediated complement activation by elevated serum levels of HDL, LDL, and apolipoproteins AI and B-100. J Control Release 2013, 170:167-174.
40. Roos A, Bouwman LH, Munoz J, Zuiverloon T, Faber-Krol MC, den Houten FC F-V, Klar-Mohamad N, Hack CE, Tilanus MG, Daha MR: Functional characterization of the lectin pathway of complement in human serum. Mol Immunol 2003, 39:655-668.
41. Chacko BK, Appukuttan PS: Dextran-binding human plasma antibody recognizes bacterial and yeast antigens and is inhibited by glucose concentrations reached in diabetic sera. Mol Immunol 2003, 39:933-939.
42. Lachmann PJ: Preparing serum for functional complement assays. J Immunol Methods 2010, 352:195-197.
43. Croize J, Arvieux J, Berche P, Colomb MG: Activation of the human complement alternative pathway by Listeria monocytogenes: evidence for direct binding and proteolysis of the C3 component on bacteria. Infect Immun 1993, 61:5134-5139.
44. Iwaki D, Kanno K, Takahashi M, Endo Y, Matsushita M, Fujita T: The role of mannose-binding lectin-associated serine protease-3 in activation of the alternative complement pathway. J Immunol 2011, 187:3751-3758.
45. Hansen S, Selman L, Palaniyar N, Ziegler K, Brandt J, Kliem A, Jonasson M, Skjoedt MO, Nielsen O, Hartshorn K, Jorgensen TJ, Skjodt K, Holmskov U: Collectin 11 (CL-11, CL-K1) is a MASP-1/3-associated plasma collectin with microbial-binding activity. J Immunol 2010, 185:6096-6104.
46. Liu Y, Endo Y, Iwaki D, Nakata M, Matsushita M, Wada I, Inoue K, Munakata M, Fujita T: Human M-ficolin is a secretory protein that activates the lectin complement pathway. J Immunol 2005, 175:3150-3156.
47. Park JH, von Maltzahn G, Zhang L, Schwartz MP, Ruoslahti E, Bhatia S, Sailor MJ: Magnetic iron oxide nanoworms for tumor targeting and imaging. Adv Mater 2008, 20:1630-1635.
48. Banda NK, Hyatt S, Antonioli AH, White JT, Glogowska M, Takahashi K, Merkel TJ, Stahl GL, Mueller-Ortiz S, Wetsel R, Arend WP, Holers VM: Role of C3a receptors, C5a receptors, and complement protein C6 deficiency in collagen antibody-induced arthritis in mice. J Immunol 2012, 188:1469-1478.
49. Coxon A, Rieu P, Barkalow FJ, Askari S, Sharpe AH, von Andrian UH, Arnaout MA, Mayadas TN: A novel role for the beta 2 integrin CD11b/CD18 in neutrophil apoptosis: a homeostatic mechanism in inflammation. Immunity 1996, 5:653-666.
50. Moller-Kristensen M, Ip WK, Shi L, Gowda LD, Hamblin MR, Thiel S, Jensenius JC, Ezekowitz RA, Takahashi K: Deficiency of mannose-binding lectin greatly increases susceptibility to postburn infection with Pseudomonas aeruginosa. J Immunol 2006, 176:1769-1775.
51. Botto M: C1q knock-out mice for the study of complement deficiency in autoimmune disease. Exp Clin Immunogenet 1998, 15:231-234.
52. Matsumoto M, Fukuda W, Circolo A, Goellner J, Strauss-Schoenberger J, Wang X, Fujita S, Hidvegi T, Chaplin DD, Colten HR: Abrogation of the alternative complement pathway by targeted deletion of murine factor B. Proc Natl Acad Sci U S A 1997, 94:8720-8725.
53. Hamada I, Hunter AC, Szebeni J, Moghimi SM: Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol Immunol 2008, 46:225-232.
54. Tan SM, Chung MC, Kon OL, Thiel S, Lee SH, Lu J: Improvements on the purification of mannan-binding lectin and demonstration of its Ca(2 +)-independent association with a C1s-like serine protease. Biochem J 1996, 319(Pt 2):329-332.